uniQure (NASDAQ:QURE) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. increased its position in shares of uniQure (NASDAQ:QURE) by 33.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,987,688 shares of the biotechnology company’s stock after buying an additional 494,726 shares during the quarter. Franklin Resources Inc. owned about 4.08% of uniQure worth $35,103,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Alliancebernstein L.P. grew its stake in shares of uniQure by 14.2% during the 4th quarter. Alliancebernstein L.P. now owns 203,919 shares of the biotechnology company’s stock worth $3,601,000 after purchasing an additional 25,319 shares during the period. JPMorgan Chase & Co. raised its stake in uniQure by 14.7% in the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company’s stock valued at $8,014,000 after purchasing an additional 58,246 shares during the last quarter. Twin Tree Management LP acquired a new position in shares of uniQure in the fourth quarter valued at approximately $77,000. Monaco Asset Management SAM purchased a new position in shares of uniQure during the fourth quarter valued at approximately $2,414,000. Finally, Raymond James Financial Inc. purchased a new stake in uniQure in the 4th quarter worth approximately $1,951,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. The trade was a 4.17 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of uniQure stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the sale, the chief financial officer now directly owns 217,730 shares in the company, valued at approximately $2,240,441.70. The trade was a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,830 shares of company stock valued at $961,401. Corporate insiders own 4.74% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ QURE opened at $8.96 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a market capitalization of $484.53 million, a price-to-earnings ratio of -1.81 and a beta of 0.37. The business has a 50-day moving average of $13.25 and a 200-day moving average of $10.94.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of uniQure in a report on Tuesday, March 4th. The Goldman Sachs Group raised their price target on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Tuesday, March 11th. Stifel Nicolaus boosted their target price on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. Finally, Leerink Partners upped their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average target price of $38.80.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.